Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLPG1205 single ascending doses, GLPG1205 film-coated tablets, GLPG1205 film-coated, [14C]-GLPG1205 solution for infusion, GLPG1205 for infusion, GLPG1205 capsules, GLPG1205 q.d
GLPG1205 · 2 trials · 2 indications
Forced vital capacity (FVC) (in milliliter \[mL\]) is the maximum amount of air exhaled from lungs by a participant after taking their deepest possible breath, as measured by spirometry.
To evaluate the efficacy of GLPG1205 in terms of changes in Mayo score comparing results at Week 8 with baseline between GLPG1205 treated subjects and placebo subjects
| Arm | Type | Description |
|---|---|---|
| GLPG1205 100 mg | EXPERIMENTAL | Participants will receive GLPG1205 100 milligrams (mg) (2 capsules x 50 mg), orally once daily for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive GLPG1205 matching placebo, orally once daily (as 2 capsules) for 26 weeks in addition to the local standard of care. Standard of care includes nintedanib, pirfenidone, or neither nintedanib nor pirfenidone. |
| GLPG1205 100mg QD | EXPERIMENTAL | GLPG1205 100mg daily dosing in the morning |
| Name | Type | Description |
|---|---|---|
| GLPG1205 | DRUG | GLPG1205 will be provided as an oral hard gelatin capsule. |
| Placebo | DRUG | GLPG1205 matching placebo will be provided as an oral hard gelatin capsule. |
Inclusion criteria: Participants who meet all of the following criteria are eligible for the study: * A diagnosis of IPF within 5 years prior to the screening visit as per applicable American Thoracic Society (ATS)/European Respiratory Society(ERS)/Japanese Respiratory Society (JRS)/Latin American...
Top 15 of 17 competitors
GLPG1205 is an investigational small molecule being studied for idiopathic pulmonary fibrosis and ulcerative colitis. It has been evaluated in Phase 2 clinical trials for both conditions. It is not approved for any indication and remains in clinical development.
GLPG1205 targets GPR84, a G protein-coupled receptor. It acts as a negative allosteric modulator of GPR84, meaning it binds to a site distinct from the receptor's natural ligand and reduces receptor signaling rather than blocking the ligand binding site directly.
GLPG1205 is being developed by Lakefront Biotherapeutics, which trades under the ticker LKFT. The company is the sponsor of the clinical trials evaluating GLPG1205 in idiopathic pulmonary fibrosis and ulcerative colitis.
GLPG1205 is in Phase 2 clinical development. It has completed Phase 2 trials in idiopathic pulmonary fibrosis and ulcerative colitis. It is investigational and has not been approved by the FDA or any other regulatory agency for any indication.
GLPG1205 has been studied in two completed Phase 2 trials. NCT03725852 evaluated its efficacy and safety in idiopathic pulmonary fibrosis with 68 participants. NCT02337608 evaluated its efficacy and safety in active ulcerative colitis with 64 participants. Both were randomized, double-blind, and placebo-controlled.
Yes. GLPG1205 film-coated tablets, GLPG1205 capsules, GLPG1205 oral suspension, and GLPG1205 for infusion are all dosage forms of the same investigational compound. The various names, including GLPG1205 50mg q.d. and GLPG1205 250 loading dose and 50mg q.d. maintenance dose, refer to different formulations or dosing regimens used in clinical studies.